Results 91 to 100 of about 4,858 (185)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, Volume 20, Issue 3, Page 779-803, March 2026.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

The Disordered Region of ASXL1 Acts as an Auto‐Regulator Through Condensation

Advanced Science, Volume 13, Issue 17, 23 March 2026.
ASXL1's long IDR encodes an electrostatic “basic platform + acidic brake” that autoregulates condensation. Truncation at a clinical hotspot lifts this brake, forming condensates that retarget BRD2, remodel local chromatin accessibility, and impair neutrophil maturation.
Xiao Fang, Qiwei Li, Wenqing Zhang
wiley   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, Volume 13, Issue 16, 18 March 2026.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Chemical probes targeting epigenetic proteins: Applications beyond oncology

Epigenetics, 2017
Epigenetic chemical probes are potent, cell-active, small molecule inhibitors or antagonists of specific domains in a protein; they have been indispensable for studying bromodomains and protein methyltransferases. The Structural Genomics Consortium (SGC),
Suzanne Ackloo, Peter J. Brown, Susanne Müller   +2 more
doaj   +1 more source

Monoaminylation in Human Health and Disease: State of the Field, Challenges, and Emerging Directions

Advanced Science, Volume 13, Issue 16, 18 March 2026.
This review delineates monoaminylation—serotonylation, dopaminylation, and histaminylation—as key post‐translational modifications beyond receptor signaling. It details their catalytic mechanisms, roles in gene expression and protein function, and implications in health and disease, aiming to bridge mechanistic insights with therapeutic potential ...
Yiqi Zhao, Hongli Zhang, Yating Yang, Wei‐Dong Chen, Yan‐Dong Wang   +4 more
wiley   +1 more source

Mechanistic role of GNE‐987 targeting BRD4‐HCP5 axis in pediatric T‐cell acute lymphoblastic leukemia

Journal of Cell Communication and Signaling, Volume 20, Issue 1, March 2026.
Abstract This study aims to explore the mechanism of action of the Bromodomain‐containing protein 4 (BRD4) inhibitor GNE‐987 in the treatment of pediatric T‐cell Acute Lymphoblastic Leukemia (T‐ALL), focusing on its effect in inhibiting T‐ALL cell proliferation by activating the HLA Complex P5 (HCP5) Super‐enhancer.
Xu Sang, Mengying Jiang, Yanchun Guan, Xin Chen, Zhen Zhang, Yumeng Wu, Wansheng Peng   +6 more
wiley   +1 more source

Case report: Diagnosis of NUT carcinoma of hepatic origin by next-generation sequencing

Frontiers in Oncology
NUT carcinoma is a rare subcategory of squamous cell carcinoma. The latter is primarily characterized by the fusion of the coding sequence NUTM1 on chromosome 15q14 with BRD4 or BRD3, both of which are acetyl-histone binding bromodomains.
Bach Ardalan, Jose Azqueta, Jia Luo, Christopher French   +3 more
doaj   +1 more source

The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
The acyl‐CoA synthetase long‐chain (ACSL) family consists of five members, which exhibit a synergistic effect in promoting tumour lipid metabolism for energy supply. Specifically, ACSL3 and ACSL4 have antagonistic effects on the mechanisms related to ferroptosis in tumour cells.
Haocai Li, Weijian Wang, Juncheng Zhan, Yuxiang Xiao, Xiaoping Chen, Chen Su, Peng Zhu   +6 more
wiley   +1 more source

Taming the Cytokine Storm: Therapeutic Strategies for Post‐Acute Sequelae of SARS‐CoV‐2 Infection

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aim Post‐acute sequelae of SARS‐CoV‐2 infection (PASC), commonly referred to as long COVID, has emerged as a significant global health concern, marked by persistent symptoms and chronic inflammation following recovery from acute COVID‐19.
Emmanuel Ifeanyi Obeagu
wiley   +1 more source